Free Trial
NASDAQ:ME

23andMe Q3 2025 Earnings Report

23andMe logo
$0.50 -0.27 (-35.32%)
Closing price 03/28/2025
Extended Trading
$0.50 0.00 (0.00%)
As of 03/28/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

23andMe EPS Results

Actual EPS
-$1.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

23andMe Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

23andMe Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Tuesday, January 28, 2025
Conference Call Time
12:30PM ET

23andMe Earnings Headlines

23andMe (NASDAQ:ME) Stock Price Down 35.3% - Time to Sell?
Massive dollar overhaul underway in D.C.?
Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in serious jeopardy leaving some to wonder – is this being done by design? A 25-year economist and investor answers here... and details the exact steps you should be taking with your money to prepare.
See More 23andMe Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 23andMe? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 23andMe and other key companies, straight to your email.

About 23andMe

23andMe (NASDAQ:ME) Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

View 23andMe Profile

More Earnings Resources from MarketBeat